Recent studies suggested that serum galectin-3 might be a potential biomarker for polycystic ovary syndrome (Anik Ilhan et al. 2018), poststroke cognitive impairment (Wang et al. 2021b) and Idiopathic inflammatory myopathies complicated by interstitial lung disease (Watanabe et al. 2021). This evidence concerns the gene LGALS3 and polycystic ovary syndrome.